Yahoo Finance

Scotiabank lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $74 from $75 and keeps an Outperform rating on the shares. The firm is impressed by the company’s regulatory and clinical execution in Q4, the analyst tells investors. Scotiabank believes Agios is well-equipped to accelerated growth of the Pyrukynd franchise and remains cautiously optimistic on mitapivat’s point of sickening.

Discover the Best Stocks and Maximize Your Portfolio:

• See what stocks are receiving strong buy ratings from top-rated analysts.

• Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on AGIO:

• Agios Pharmaceuticals Reports Strong 2024 Financial Results

• Agios Pharmaceuticals Earnings Call Highlights Growth & Pipeline Progress

• Agios Pharma: Promising Growth with Strategic Market Expansion and Pipeline Advancements

• Agios Pharmaceuticals reports Q4 revenue $10.7M, consensus $9.35M

• Agios Pharmaceuticals reports results from Phase 3 ACTIVATE-Kids study